MA50144A - Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées - Google Patents

Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées

Info

Publication number: MA50144A
Authority: MA; Morocco
Prior art keywords: n3pglu; peptid; beta; amyloid antibodies; associated uses
Prior art date: 2017-04-20

Application number

MA050144A

Other languages

English (en)

Inventor

Ronald Bradley Demattos

Jirong Lu

Ying Tang

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-04-20

Filing date

2018-04-16

Publication date

2020-07-29

2018-04-16 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2020-07-29 Publication of MA50144A publication Critical patent/MA50144A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Hospice & Palliative Care (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

MA050144A 2017-04-20 2018-04-16 Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées MA50144A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762487550P	2017-04-20	2017-04-20

Publications (1)

Publication Number	Publication Date
MA50144A true MA50144A (fr)	2020-07-29

Family

ID=62111232

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050144A MA50144A (fr)	2017-04-20	2018-04-16	Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées

Country Status (28)

Country	Link
US (3)	US10647759B2 (fr)
EP (1)	EP3612559A1 (fr)
JP (3)	JP6900500B2 (fr)
KR (2)	KR102567295B1 (fr)
CN (2)	CN110582511B (fr)
AR (1)	AR111208A1 (fr)
AU (2)	AU2018255221B2 (fr)
BR (1)	BR112019018810A2 (fr)
CA (1)	CA3058482C (fr)
CL (1)	CL2019002922A1 (fr)
CO (1)	CO2019011349A2 (fr)
CR (1)	CR20190445A (fr)
DO (1)	DOP2019000241A (fr)
EA (1)	EA201992163A1 (fr)
EC (1)	ECSP19075146A (fr)
IL (1)	IL269003B2 (fr)
JO (1)	JOP20190247A1 (fr)
MA (1)	MA50144A (fr)
MX (2)	MX2019012445A (fr)
NZ (1)	NZ758066A (fr)
PE (1)	PE20200011A1 (fr)
PH (1)	PH12019502361A1 (fr)
SA (1)	SA519410311B1 (fr)
SG (1)	SG11201909022PA (fr)
TW (2)	TWI789644B (fr)
UA (1)	UA126806C2 (fr)
WO (1)	WO2018194951A1 (fr)
ZA (1)	ZA202007868B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201827467A (zh)	2016-11-03	2018-08-01	比利時商健生藥品公司	焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) *	2017-04-20	2019-10-20	Lilly Co Eli	أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
WO2020193644A1 (fr)	2019-03-26	2020-10-01	Janssen Pharmaceutica Nv	Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
WO2021151011A2 (fr) *	2020-01-24	2021-07-29	The Board Of Trustees Of Western Michigan University	Traitement de protéinopathies neurodégénératives à l'aide d'une molécule inhibitrice de l'apoptose fas (faim) ou d'un de ses fragments et/ou mimétiques
CN116348486A (zh) *	2020-10-02	2023-06-27	伊莱利利公司	在蛋白质纯化过程中降低宿主细胞蛋白质含量的方法
TWI843040B (zh)	2021-01-11	2024-05-21	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途
TW202300518A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗類澱粉β抗體及其用途
WO2022251048A1 (fr)	2021-05-24	2022-12-01	Eli Lilly And Company	Anticorps anti-amyloïde bêta et leurs utilisations
JP7306745B2 (ja) *	2021-09-16	2023-07-11	株式会社ユニバーサルエンターテインメント	遊技機
JP7306746B2 (ja) *	2021-09-16	2023-07-11	株式会社ユニバーサルエンターテインメント	遊技機
JP7268910B2 (ja) *	2021-09-16	2023-05-08	株式会社ユニバーサルエンターテインメント	遊技機
WO2023070064A1 (fr)	2021-10-22	2023-04-27	Eli Lilly And Company	Polythérapie par un inhibiteur d'o-glcnacase (oga)
TW202334210A (zh)	2021-10-29	2023-09-01	美商美國禮來大藥廠	靶向介白素-34之化合物及方法
PE20241471A1 (es)	2021-10-29	2024-07-17	Lilly Co Eli	Compuestos y metodos dirigidos a la interleucina-34
KR20240099348A (ko)	2021-10-29	2024-06-28	일라이 릴리 앤드 캄파니	인터류킨-34를 표적화하는 화합물 및 방법
CA3236504A1 (fr)	2021-10-29	2023-05-04	Eli Lilly Company	Composes et procedes ciblant l'interleukine-34
IL314657A (en)	2022-02-03	2024-09-01	Lilly Co Eli	Regional tau imaging for diagnosing and treating alzheimer's disease
CN117327168A (zh) *	2022-06-24	2024-01-02	厦门大学	B2M-GluN1封闭肽、其药物组合物及用途
JP2025540659A (ja) *	2022-11-17	2025-12-16	イーライリリーアンドカンパニー	抗Ｎ３ｐＧｌｕアミロイドベータ抗体、用量、及びその使用
IL321331A (en)	2022-12-22	2025-08-01	Bioarctic Ab	Antibody that binds to ABETAPE3
WO2025106313A1 (fr)	2023-11-14	2025-05-22	Eli Lilly And Company	Dosages basés sur récepteur fc destinés à l'analyse d'anticorps igg
WO2025228316A1 (fr) *	2024-04-28	2025-11-06	Jacobio Pharmaceuticals Co., Ltd.	Anticorps anti-bêta-amyloïdes n3pglu et leurs utilisations
US20250388664A1 (en)	2024-06-20	2025-12-25	Bioarctic Ab	Bispecific binding molecule
CN118459583B (zh) *	2024-07-11	2024-09-10	齐鲁制药有限公司	抗N3pGlu淀粉样蛋白β抗体及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001062801A2 (fr) *	2000-02-24	2001-08-30	Washington University	Anticorps humanises sequestrant un peptide a$g(b)
US7122374B1 (en)	2002-04-09	2006-10-17	Takaomi Saido	Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
CA2487528A1 (fr)	2002-07-24	2004-02-12	Innogenetics N.V.	Prevention, traitement et diagnostic de maladies associees a la formation et/ou a l'agregation de la beta-amyloide
US20070031416A1 (en)	2003-09-09	2007-02-08	Takeda Pharmaceutical Company Limited	Use of antibody
MX2007000998A (es)	2004-07-30	2007-07-11	Rinat Neuroscience Corp	Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
PE20061323A1 (es) *	2005-04-29	2007-02-09	Rinat Neuroscience Corp	Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
PL2468770T3 (pl)	2006-07-14	2018-07-31	Ac Immune S.A.	Humanizowane przeciwciało przeciw amyloidowi beta
AU2009257170B2 (en)	2008-06-12	2014-06-12	Affiris Ag	Compounds for treating symptoms associated with Parkinson's disease
US20110182809A1 (en)	2008-07-09	2011-07-28	University Of Zurich	Method of Promoting Neurogenesis
NZ590563A (en)	2008-07-21	2012-06-29	Probiodrug Ag	Diagnostic antibody assay
WO2011151076A2 (fr)	2010-06-04	2011-12-08	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin	Anticorps monoclonaux ciblant des oligomères aβ
WO2012021475A2 (fr) *	2010-08-12	2012-02-16	Eli Lilly And Company	ANTICORPS CONTRE LE PEPTIDE N3pGLU AMYLOÏDE BÊTA ET LEURS UTILISATIONS
LT3339323T (lt) *	2010-08-12	2020-02-10	Eli Lilly And Company	Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas
WO2015175769A1 (fr) *	2014-05-15	2015-11-19	Biogen Ma Inc.	Procédés de détection d'oligomères bêta-amyloïdes dans des échantillons biologiques
TWI599358B (zh) *	2014-09-16	2017-09-21	美國禮來大藥廠	組合療法
PL3988117T3 (pl) *	2015-04-13	2025-03-10	Pfizer Inc.	Przeciwciała terapeutyczne i ich zastosowania
JOP20170004B1 (ar) *	2016-01-15	2022-09-15	Lilly Co Eli	الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh) *	2016-07-01	2021-08-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
JOP20190247A1 (ar) *	2017-04-20	2019-10-20	Lilly Co Eli	أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها

2017
- 2017-06-16 JO JOP/2019/0247A patent/JOP20190247A1/ar unknown
2018
- 2018-04-09 TW TW109140166A patent/TWI789644B/zh active
- 2018-04-09 AR ARP180100882A patent/AR111208A1/es unknown
- 2018-04-09 TW TW107112023A patent/TWI705975B/zh active
- 2018-04-16 AU AU2018255221A patent/AU2018255221B2/en active Active
- 2018-04-16 SG SG11201909022P patent/SG11201909022PA/en unknown
- 2018-04-16 KR KR1020227001314A patent/KR102567295B1/ko active Active
- 2018-04-16 WO PCT/US2018/027718 patent/WO2018194951A1/fr not_active Ceased
- 2018-04-16 PE PE2019002050A patent/PE20200011A1/es unknown
- 2018-04-16 JP JP2019551563A patent/JP6900500B2/ja active Active
- 2018-04-16 IL IL269003A patent/IL269003B2/en unknown
- 2018-04-16 EA EA201992163A patent/EA201992163A1/ru unknown
- 2018-04-16 MX MX2019012445A patent/MX2019012445A/es unknown
- 2018-04-16 CA CA3058482A patent/CA3058482C/fr active Active
- 2018-04-16 EP EP18722325.0A patent/EP3612559A1/fr active Pending
- 2018-04-16 CN CN201880025982.6A patent/CN110582511B/zh active Active
- 2018-04-16 UA UAA201910202A patent/UA126806C2/uk unknown
- 2018-04-16 CN CN202310757235.4A patent/CN117024583A/zh active Pending
- 2018-04-16 BR BR112019018810A patent/BR112019018810A2/pt unknown
- 2018-04-16 US US15/953,716 patent/US10647759B2/en active Active
- 2018-04-16 CR CR20190445A patent/CR20190445A/es unknown
- 2018-04-16 MA MA050144A patent/MA50144A/fr unknown
- 2018-04-16 KR KR1020197030416A patent/KR102352670B1/ko active Active
- 2018-04-16 NZ NZ758066A patent/NZ758066A/en unknown
2019
- 2019-09-20 DO DO2019000241A patent/DOP2019000241A/es unknown
- 2019-10-14 CL CL2019002922A patent/CL2019002922A1/es unknown
- 2019-10-15 CO CO2019011349A patent/CO2019011349A2/es unknown
- 2019-10-16 SA SA519410311A patent/SA519410311B1/ar unknown
- 2019-10-17 PH PH12019502361A patent/PH12019502361A1/en unknown
- 2019-10-17 MX MX2022011817A patent/MX2022011817A/es unknown
- 2019-10-18 EC ECSENADI201975146A patent/ECSP19075146A/es unknown
2020
- 2020-04-08 US US16/843,503 patent/US11078261B2/en active Active
- 2020-12-17 ZA ZA2020/07868A patent/ZA202007868B/en unknown
2021
- 2021-06-14 AU AU2021203927A patent/AU2021203927B2/en active Active
- 2021-06-16 JP JP2021099897A patent/JP7227312B2/ja active Active
- 2021-08-02 US US17/391,821 patent/US20210371509A1/en not_active Abandoned
2023
- 2023-02-09 JP JP2023018535A patent/JP7532571B2/ja active Active

Also Published As

Publication number	Publication date
IL269003B1 (en)	2025-06-01
US10647759B2 (en)	2020-05-12
CL2019002922A1 (es)	2020-03-13
PE20200011A1 (es)	2020-01-06
TW201902924A (zh)	2019-01-16
JOP20190247A1 (ar)	2019-10-20
SA519410311B1 (ar)	2022-03-20
TW202120541A (zh)	2021-06-01
JP2021151253A (ja)	2021-09-30
MX2019012445A (es)	2020-01-13
AR111208A1 (es)	2019-06-12
BR112019018810A2 (pt)	2020-05-05
TWI705975B (zh)	2020-10-01
DOP2019000241A (es)	2019-10-15
CN110582511B (zh)	2023-08-08
KR102352670B1 (ko)	2022-01-19
EP3612559A1 (fr)	2020-02-26
CR20190445A (es)	2019-11-06
KR20190129100A (ko)	2019-11-19
AU2018255221A1 (en)	2019-09-19
CA3058482C (fr)	2023-05-09
AU2018255221B2 (en)	2021-07-01
US20180305444A1 (en)	2018-10-25
NZ758066A (en)	2022-10-28
US11078261B2 (en)	2021-08-03
US20210371509A1 (en)	2021-12-02
JP2020510081A (ja)	2020-04-02
WO2018194951A1 (fr)	2018-10-25
IL269003A (en)	2019-10-31
CA3058482A1 (fr)	2018-10-25
KR20220011800A (ko)	2022-01-28
CN117024583A (zh)	2023-11-10
MX2022011817A (es)	2022-10-10
EA201992163A1 (ru)	2020-03-02
KR102567295B1 (ko)	2023-08-16
CN110582511A (zh)	2019-12-17
AU2021203927B2 (en)	2024-03-21
PH12019502361A1 (en)	2020-07-13
ECSP19075146A (es)	2019-10-31
JP6900500B2 (ja)	2021-07-07
JP7227312B2 (ja)	2023-02-21
JP7532571B2 (ja)	2024-08-13
CO2019011349A2 (es)	2019-10-31
IL269003B2 (en)	2025-10-01
US20200262902A1 (en)	2020-08-20
TWI789644B (zh)	2023-01-11
JP2023058623A (ja)	2023-04-25
AU2021203927A1 (en)	2021-07-08
UA126806C2 (uk)	2023-02-08
ZA202007868B (en)	2023-06-28
SG11201909022PA (en)	2019-11-28

Publication	Publication Date	Title
MA50144A (fr)	2020-07-29	Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées
EP3762030A4 (fr)	2022-01-05	Anticorps anti-cd73 et utilisations associées
EP3625263A4 (fr)	2021-05-05	Anticorps anti-galectine-9 et leurs utilisations
EP3383916A4 (fr)	2019-09-11	Anticorps anti-cd73 et leurs utilisations
EP3891183A4 (fr)	2022-08-31	Anticorps anti-claudine et leurs utilisations
EP3389702A4 (fr)	2019-08-14	Anticorps anti-lag-3 et leurs utilisations
EP3838289A4 (fr)	2022-08-03	Anticorps anti-tigit et ses utilisations
EP3626825A4 (fr)	2021-02-17	Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
MA47789A (fr)	2020-01-22	Anticorps anti-phf-tau et leurs utilisations
EP3504243A4 (fr)	2020-03-11	Anticorps anti-tim-3 et leurs utilisations
EP3759143A4 (fr)	2022-03-02	Anticorps anti-tigit et leurs utilisations
EP3658589C0 (fr)	2023-09-27	Anticorps anti-sirp-alpha et méthodes associées
EP3426288A4 (fr)	2019-10-30	Anticorps anti-pacap et leurs utilisations
MA49683A (fr)	2020-06-03	Anticorps anti-cd8 et leurs utilisations
EP3733702A4 (fr)	2021-09-29	Anticorps anti-lag-3 et utilisations associées
MA46704A (fr)	2019-09-11	Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3735427A4 (fr)	2021-09-15	Anticorps anti-mct1 et utilisations associées
EP3684812A4 (fr)	2021-09-08	Anticorps anti-ctla4 et utilisations associées
MA46708A (fr)	2021-05-05	Anticorps anti-pd1 et leurs utilisations
MA49886A (fr)	2020-06-24	Anticorps anti-par2 et leurs utilisations
MA49537A (fr)	2020-05-13	Anticorps anti-lag3 et leurs utilisations
MA45125A (fr)	2021-06-02	Anticorps anti-alpha-synucléine et leurs utilisations
MA45690A (fr)	2019-05-22	Anticorps anti-tgfb, méthodes et utilisations
EP3283516A4 (fr)	2019-03-06	Anticorps anti-pacap et leurs utilisations
EP3645563A4 (fr)	2021-03-17	Anticorps anti-fam19a5 et leurs utilisations